| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
26,020,000 |
| Market
Cap: |
241.21(M) |
| Last
Volume: |
6,675 |
Avg
Vol: |
6,656 |
| 52
Week Range: |
$6.48 - $11.61 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Home Health Care |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fennec Pharmaceuticals is a biopharmaceutical company focused on the development of PEDMARK™ (sodium thiosulfate anhydrous injection) for the prevention of platinum-induced ototoxicity in pediatric cancer patients. Co. has licensed from Oregon Health & Science University intellectual property rights for the use of PEDMARK™ as a chemoprotectant and is developing PEDMARK™ as a protectant against the hearing loss caused by platinum-based anti-cancer agents in children.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
41,667 |
41,667 |
41,667 |
41,667 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
2 |
2 |
2 |
2 |
| Total Shares Sold |
384,683 |
445,042 |
481,476 |
532,549 |
| Total Sell Value |
$3,266,840 |
$3,836,454 |
$4,152,217 |
$4,642,390 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
18 |
24 |
31 |
38 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-12-30 |
4 |
S |
$9.61 |
$96,207 |
D/D |
(10,000) |
217,838 |
|
18% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2022-12-30 |
4 |
AS |
$9.61 |
$52,867 |
D/D |
(5,500) |
149,721 |
|
-18% |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-12-29 |
4 |
S |
$9.65 |
$48,250 |
D/D |
(5,000) |
227,838 |
|
18% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2022-12-29 |
4 |
AS |
$9.57 |
$52,661 |
D/D |
(5,500) |
155,221 |
|
-18% |
|
| Raykov Rosty |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-12-28 |
4 |
S |
$9.59 |
$131,767 |
D/D |
(13,740) |
232,838 |
|
18% |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2022-12-28 |
4 |
AS |
$9.61 |
$105,760 |
D/D |
(11,000) |
160,721 |
|
-18% |
|
| Rallis Chris A |
|
– • – |
2022-11-17 |
4 |
AS |
$7.99 |
$2,661 |
D/D |
(333) |
30,018 |
|
2% |
|
| Rallis Chris A |
|
– • – |
2022-10-20 |
4 |
D |
$8.26 |
$17,082 |
D/D |
(2,068) |
30,351 |
|
- |
|
| Rallis Chris A |
|
– • – |
2022-10-20 |
4 |
OE |
$1.05 |
$5,000 |
D/D |
4,762 |
32,419 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2022-09-21 |
4 |
D |
$8.54 |
$162,704 |
D/D |
(19,052) |
171,721 |
|
- |
|
| Andrade Robert |
CHIEF FINANCIAL OFFICER |
• – – |
2022-09-21 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
190,773 |
|
- |
|
| Rallis Chris A |
Director |
– • – |
2022-07-18 |
4 |
D |
$6.70 |
$29,339 |
D/D |
(4,379) |
27,657 |
|
- |
|
| Rallis Chris A |
Director |
– • – |
2022-07-18 |
4 |
OE |
$0.45 |
$5,000 |
D/D |
11,111 |
32,036 |
|
- |
|
| Rallis Chris A |
Director |
– • – |
2022-03-08 |
4 |
OE |
$0.54 |
$10,000 |
D/D |
17,592 |
20,925 |
|
- |
|
| Rallis Chris A |
Director |
– • – |
2021-10-21 |
4 |
OE |
$1.50 |
$5,000 |
D/D |
3,333 |
3,333 |
|
- |
|
| Raykov Rosty |
Chief Executive Officer |
• • – |
2020-08-17 |
4 |
D |
$5.71 |
$69,051 |
D/D |
(12,093) |
196,578 |
|
- |
|
| Andrade Robert |
Chief Financial Officer |
• – – |
2020-08-17 |
4 |
D |
$5.71 |
$73,511 |
D/D |
(12,874) |
153,273 |
|
- |
|
| Raykov Rosty |
Chief Executive Officer |
• • – |
2020-08-14 |
4 |
D |
$5.68 |
$215,914 |
D/D |
(38,013) |
208,671 |
|
- |
|
| Andrade Robert |
Chief Financial Officer |
• – – |
2020-08-14 |
4 |
D |
$5.68 |
$220,952 |
D/D |
(38,900) |
166,147 |
|
- |
|
| Raykov Rosty |
Chief Executive Officer |
• • – |
2020-08-13 |
4 |
D |
$5.77 |
$818,191 |
D/D |
(135,067) |
246,684 |
|
- |
|
| Raykov Rosty |
Chief Executive Officer |
• • – |
2020-08-13 |
4 |
OE |
$1.85 |
$599,328 |
D/D |
323,961 |
381,751 |
|
- |
|
| Andrade Robert |
Chief Financial Officer |
• – – |
2020-08-13 |
4 |
D |
$5.77 |
$823,367 |
D/D |
(135,964) |
205,047 |
|
- |
|
| Andrade Robert |
Chief Financial Officer |
• – – |
2020-08-13 |
4 |
OE |
$1.85 |
$599,328 |
D/D |
323,961 |
341,011 |
|
- |
|
| Clark John Smith Ii |
10% Owner |
– – • |
2020-05-04 |
4 |
B |
$6.25 |
$500,000 |
I/I |
80,000 |
4,077,214 |
1.5 |
-11% |
|
| Cavazza Preta Martina |
10% Owner |
– – • |
2020-04-30 |
4 |
B |
$6.25 |
$4,800,000 |
D/D |
768,000 |
3,993,694 |
2.45 |
-21% |
|
268 Records found
|
|
Page 3 of 11 |
|
|
0.08 (0.86%) 
